- Market Capitalization, $K 1,014,915
- Shares Outstanding, K 66,683
- Annual Sales, $ 6,760 K
- Annual Income, $ -90,870 K
- 60-Month Beta 0.55
- Price/Sales 155.74
- Price/Cash Flow N/A
- Price/Book 4.79
|Period||Period Low||Period High||Performance|
| || |
-0.16 (-0.98%)since 11/01/22
| || |
-1.38 (-8.00%)since 09/01/22
| || |
+3.33 (+26.64%)since 12/01/21
Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.
Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris: Q3 Earnings Snapshot
Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022...
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.
Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
|S&P Pharmaceuticals SPDR|
|Pharmaceutical & Medical Bull 3X Direxion|
|Principal Healthcare Innovators Index|
|Micro-Cap Ishares ETF|
|Invesco Nasdaq Biotechnology ETF|
|3rd Resistance Point||17.08|
|2nd Resistance Point||16.62|
|1st Resistance Point||15.92|
|1st Support Level||14.77|
|2nd Support Level||14.31|
|3rd Support Level||13.61|